Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Next Previous
X
Search
Trial Profile

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dordaviprone (Primary)
  • Indications Diffuse intrinsic pontine glioma; Glioma
  • Focus Expanded access; Therapeutic Use
  • Sponsors Chimerix

    • Most Recent Events

    • 26 Apr 2022 Results assessing the demographic, clinical, and molecular characteristics of three adult subjects receiving ONC-201, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
    • 19 Nov 2021 According to the Chimerix media release, positive data from its 50-patient efficacy analysis from ONC006, ONC013, ONC014, ONC016, or ONC018 studies will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting 2021.
    • 19 Nov 2021 Pooled data presented in a Chimerix media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top